Contagion Live news story
Asuptegravir (Jiangsu Aidea Pharmaceutical), an investigational integrase strand transfer inhibitor, reduced HIV-1 RNA by 1.49 to 2.36 log10 copies/mL after 10 days of monotherapy in treatment-naive people with HIV, with a clear dose-response relationship. Hong Qin, MD, PhD, chief medical officer of Aidea, presented phase 1 and phase 1/2 data at IDWeek 2026, held October 21-24 in Washington, DC. A third poster reported final 48-week results from the RECOVER study of fostemsavir in immunologic nonresponders.
Asuptegravir is metabolized by UGT1A1 and is being evaluated alongside emtricitabine and tenofovir alafenamide. Immunologic nonresponders, defined as people with CD4+ T-cell counts persistently below 350 cells/mm3 despite at least 2 years of viral suppression, face higher risks of AIDS progression, non-AIDS events, and death.
Read the full news story here.
View all Contagion Live reports from IDWeek 2026
Source : Contagion Live
Related HIV and Co-Infections News
-
[IDWeek 2026] Infectious Disease Advisor | Novel doravirine/islatravir yields similar patient-reported outcomes in HIV-1
-
[IDWeek 2026] Infectious Disease Advisor | Bictegravir/lenacapavir well tolerated in people with HIV and comorbidities
-
LSHTM | Six injections a year instead of 365 pills: Can long-acting HIV treatment change care in Africa?
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.